UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 124

Sortiert nach

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Journal of clinical oncology, 2009-12, Vol.27 (34), p.5794-5799

2009

Link zum Volltext

Verfügbarkeit prüfen

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

Cancer immunology research, 2015-10, Vol.3 (10), p.1158-1164

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group

Journal of clinical oncology, 2008-12, Vol.26 (35), p.5748-5754

2008

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2005-01, Vol.23 (1), p.133-141

2005

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Journal of clinical oncology, 2004-03, Vol.22 (5), p.909-918

2004

Link zum Volltext

Verfügbarkeit prüfen

A case of checkpoint inhibitor-induced celiac disease

Journal for immunotherapy of cancer, 2019-08, Vol.7 (1), p.203-203, Article 203

2019

Link zum Volltext

Verfügbarkeit prüfen

BRAF Mutations in Metanephric Adenoma of the Kidney

European urology, 2012-11, Vol.62 (5), p.917-922

2012

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

Journal of clinical oncology, 2018-02, Vol.36 (4), p.391-398

2018

Link zum Volltext

Verfügbarkeit prüfen

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Journal of clinical oncology, 2021-03, Vol.39 (9), p.1029-1039

2021

Link zum Volltext

Verfügbarkeit prüfen

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma

Clinical cancer research, 2017-07, Vol.23 (14), p.3557-3565

2017

Link zum Volltext

Verfügbarkeit prüfen

Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study

The lancet oncology, 2013, Vol.14 (1), p.81-87

2013

Link zum Volltext

Verfügbarkeit prüfen

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

Journal of clinical oncology, 2021-03, Vol.39 (9), p.1020-1028

2021

Link zum Volltext

Verfügbarkeit prüfen

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

Journal of immunotherapy (1997), 2005-09, Vol.28 (5), p.488

2005

Link zum Volltext

Verfügbarkeit prüfen

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

Journal of clinical oncology, 2015-06, Vol.33 (18), p.2013-2020

2015

Link zum Volltext

Verfügbarkeit prüfen

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors

Journal of clinical oncology, 2020-09, Vol.38 (27), p.3088-3094

2020

Link zum Volltext

Verfügbarkeit prüfen

Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma

Journal of clinical oncology, 2008-05, Vol.26 (14), p.2292-2298

2008

Link zum Volltext

Verfügbarkeit prüfen

Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)

Urologic oncology, 2013-11, Vol.31 (8), p.1788-1793

2013

Link zum Volltext

Verfügbarkeit prüfen

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)

Journal of clinical oncology, 2015-07, Vol.33 (21), p.2384-2391

2015

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab plus ipilimumab in patients with metastatic melanoma

Cancer immunology research, 2014-07, Vol.2 (7), p.632-642

2014

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)

Journal of clinical oncology, 2015-12, Vol.33 (34), p.4066-4076

2015

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial

JAMA oncology, 2017-09, Vol.3 (9), p.1249

2017

Link zum Volltext

Verfügbarkeit prüfen

Effects of the Administration of High-Dose Interleukin-2 on Immunoregulatory Cell Subsets in Patients with Advanced Melanoma and Renal Cell Cancer

Clinical cancer research, 2007-04, Vol.13 (7), p.2100-2108

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 124

Suche als RSS-Feed

Aktive Filter

KollektionAUTh Library subscriptions: Taylor & Francis Journals

ThemaImmunotherapy

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(119)
Mit Volltextzugriff
(107)

Publikationsform

Artikel
(124)

Sprache

Englisch
(124)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Humans
(124)
Science & Technology
(121)
Life Sciences & Biomedicine
(119)
Male
(116)
Female
(109)
Middle Aged
(109)
Adult
(88)
Oncology
(74)
Aged, 80 And Over
(51)
Biological And Medical Sciences
(38)
Medical Sciences
(37)
Treatment Outcome
(34)
Carcinoma, Renal Cell - Drug Therapy
(31)
Kidney Neoplasms - Drug Therapy
(30)
Melanoma - Drug Therapy
(25)
Kidney Neoplasms - Pathology
(23)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(22)
Carcinoma, Renal Cell - Pathology
(20)
Neoplasm Staging
(19)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

A case of checkpoint inhibitor-induced celiac disease

BRAF Mutations in Metanephric Adenoma of the Kidney

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma

Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors

Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma

Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma

Bevacizumab plus ipilimumab in patients with metastatic melanoma

Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial

Effects of the Administration of High-Dose Interleukin-2 on Immunoregulatory Cell Subsets in Patients with Advanced Melanoma and Renal Cell Cancer

Aktive Filter

Suchergebnisse filtern